Summary Gala GLP-1 is a prescription telehealth platform operated by AI Coaching, Inc., designed to connect patients with licensed healthcare providers for GLP-1 and GLP-1/GIP weight management consultations across all 50 states
Preferred injection sites include the abdomen (at least two inches from the navel), the front of the thigh, and the back of the upper arm
Most patients see modest changes that resolve once a stable dose is reached
Investigators highlighted pooled analysis indicated changes in 24-hour systolic blood pressure correlated with change in body weight (r = .31
Findings: Change in body weight : The mean percent change in body weight was -20.2% with tirzepatide (95% CI, -21.4 to -19.1) and -13.7% with semaglutide (95% CI, -14.9 to -12.6)
A tirzepatide research peptide is a lyophilized synthetic dual incretin receptor agonist (GLP2-T / LY3298176) supplied for in-vitro, analytical, and preclinical laboratory research